RaQualia Pharma Inc. (4579.T)
JPY 377.0
(-1.31%)
JPY 377.0
(-1.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 809.83 Million JPY | 6.46% |
| 2022 | 760.67 Million JPY | 70.48% |
| 2021 | 446.19 Million JPY | 85.83% |
| 2020 | 240.1 Million JPY | 11.2% |
| 2019 | 215.91 Million JPY | 10.6% |
| 2018 | 195.21 Million JPY | 10.77% |
| 2017 | 176.23 Million JPY | -23.8% |
| 2016 | 231.28 Million JPY | -2.72% |
| 2015 | 237.74 Million JPY | -55.21% |
| 2014 | 530.77 Million JPY | -41.16% |
| 2013 | 902.09 Million JPY | 373.0% |
| 2012 | 190.71 Million JPY | -6.82% |
| 2011 | 204.67 Million JPY | -24.09% |
| 2010 | 269.62 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.69 Billion JPY | 479.86% |
| 2024 Q2 | 4.47 Billion JPY | -4.65% |
| 2023 Q2 | 706.45 Million JPY | 0.02% |
| 2023 FY | 809.83 Million JPY | 6.46% |
| 2023 Q4 | 809.83 Million JPY | 10.51% |
| 2023 Q3 | 732.83 Million JPY | 3.73% |
| 2023 Q1 | 706.33 Million JPY | -7.14% |
| 2022 Q1 | 524.56 Million JPY | 17.56% |
| 2022 Q2 | 678.06 Million JPY | 29.26% |
| 2022 Q4 | 760.67 Million JPY | 26.0% |
| 2022 FY | 760.67 Million JPY | 70.48% |
| 2022 Q3 | 603.69 Million JPY | -10.97% |
| 2021 FY | 446.19 Million JPY | 85.83% |
| 2021 Q1 | 410.17 Million JPY | 70.83% |
| 2021 Q2 | 425.4 Million JPY | 3.71% |
| 2021 Q3 | 294.23 Million JPY | -30.84% |
| 2021 Q4 | 446.19 Million JPY | 51.65% |
| 2020 Q4 | 240.1 Million JPY | 12.9% |
| 2020 Q2 | 213.06 Million JPY | -0.51% |
| 2020 FY | 240.1 Million JPY | 11.2% |
| 2020 Q1 | 214.16 Million JPY | -0.81% |
| 2020 Q3 | 212.67 Million JPY | -0.18% |
| 2019 Q1 | 236.3 Million JPY | 21.05% |
| 2019 Q2 | 143.75 Million JPY | -39.16% |
| 2019 Q3 | 153.48 Million JPY | 6.77% |
| 2019 Q4 | 215.91 Million JPY | 40.67% |
| 2019 FY | 215.91 Million JPY | 10.6% |
| 2018 Q3 | 306.29 Million JPY | 16.04% |
| 2018 Q2 | 263.97 Million JPY | 30.56% |
| 2018 Q4 | 195.21 Million JPY | -36.27% |
| 2018 FY | 195.21 Million JPY | 10.77% |
| 2018 Q1 | 202.19 Million JPY | 14.73% |
| 2017 Q2 | 168.39 Million JPY | -38.73% |
| 2017 FY | 176.23 Million JPY | -23.8% |
| 2017 Q4 | 176.23 Million JPY | -1.83% |
| 2017 Q3 | 179.52 Million JPY | 6.61% |
| 2017 Q1 | 274.82 Million JPY | 18.83% |
| 2016 FY | 231.28 Million JPY | -2.72% |
| 2016 Q1 | 275.73 Million JPY | 15.98% |
| 2016 Q2 | 432.4 Million JPY | 56.82% |
| 2016 Q3 | 219.76 Million JPY | -49.18% |
| 2016 Q4 | 231.28 Million JPY | 5.24% |
| 2015 FY | 237.74 Million JPY | -55.21% |
| 2015 Q1 | 311.07 Million JPY | -41.39% |
| 2015 Q2 | 294.59 Million JPY | -5.3% |
| 2015 Q4 | 237.74 Million JPY | 13.35% |
| 2015 Q3 | 209.75 Million JPY | -28.8% |
| 2014 FY | 530.77 Million JPY | -41.16% |
| 2014 Q3 | 597.12 Million JPY | -34.88% |
| 2014 Q4 | 530.77 Million JPY | -11.11% |
| 2014 Q2 | 917.01 Million JPY | 3.07% |
| 2014 Q1 | 889.66 Million JPY | -1.38% |
| 2013 Q3 | 991.66 Million JPY | 120.68% |
| 2013 Q1 | 216.44 Million JPY | 13.49% |
| 2013 FY | 902.09 Million JPY | 373.0% |
| 2013 Q2 | 449.36 Million JPY | 107.62% |
| 2013 Q4 | 902.09 Million JPY | -9.03% |
| 2012 Q4 | 190.71 Million JPY | -18.32% |
| 2012 Q1 | 236.38 Million JPY | 15.5% |
| 2012 Q3 | 233.49 Million JPY | 2.51% |
| 2012 Q2 | 227.77 Million JPY | -3.64% |
| 2012 FY | 190.71 Million JPY | -6.82% |
| 2011 Q4 | 204.67 Million JPY | -71.05% |
| 2011 Q3 | 706.94 Million JPY | 278.35% |
| 2011 Q2 | 186.85 Million JPY | 0.0% |
| 2011 FY | 204.67 Million JPY | -24.09% |
| 2010 FY | 269.62 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 75.059% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -1177.113% |
| GNI Group Ltd. | 26.34 Billion JPY | 96.926% |
| Linical Co., Ltd. | 10.3 Billion JPY | 92.141% |
| Trans Genic Inc. | 3.81 Billion JPY | 78.759% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -37.212% |
| Soiken Holdings Inc. | 697.02 Million JPY | -16.184% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 73.191% |
| AnGes, Inc. | 2.78 Billion JPY | 70.967% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -57.675% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.104% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -129.238% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 50.916% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -71.445% |
| CanBas Co., Ltd. | 91.98 Million JPY | -780.365% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 25.949% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -36.397% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 80.963% |
| PeptiDream Inc. | 29.11 Billion JPY | 97.218% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -42.953% |
| Ribomic Inc. | 155.8 Million JPY | -419.758% |
| SanBio Company Limited | 2.25 Billion JPY | 64.086% |
| Healios K.K. | 11.28 Billion JPY | 92.824% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -222.296% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -119.466% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -235.337% |
| StemRIM | 187 Million JPY | -333.064% |
| CellSource Co., Ltd. | 677.73 Million JPY | -19.49% |
| FunPep Company Limited | 189.32 Million JPY | -327.748% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -35.66% |
| Stella Pharma Corporation | 1.44 Billion JPY | 43.902% |
| TMS Co., Ltd. | 97.68 Million JPY | -728.988% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -785.118% |
| Cuorips Inc. | 200.96 Million JPY | -302.979% |
| K Pharma,Inc. | 209.13 Million JPY | -287.23% |
| Takara Bio Inc. | 11.42 Billion JPY | 92.909% |
| ReproCELL Incorporated | 741.03 Million JPY | -9.284% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 11.756% |
| StemCell Institute Inc. | 3.85 Billion JPY | 78.968% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 10.854% |
| CellSeed Inc. | 301.04 Million JPY | -169.005% |